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ABSTRACT
Introduction: E-cigarettes or electronic nicotine
delivery systems (ENDS) have recently attracted
considerable attention. Among some individuals there
is strong debate and a polarisation of views about the
public health benefits versus harms of ENDS. With
little regulation, the ENDS market is evolving, and new
products are introduced and marketed constantly.
Rapid developments in manufacturing, marketing and
consumer domains related to ENDS will warrant
frequent re-evaluation, based on the state of the
evolving science. The purpose of this article is to
describe a protocol for an ongoing comprehensive
review of the published scientific literature on ENDS.
Methods and analysis: We will undertake a
systematic review of published empirical research
literature on ENDS using the National Library of
Medicine’s PubMed electronic database to search for
relevant articles. Data from included studies will be
extracted into a standardised form, tables with study
details and key outcomes for each article will be
created, and studies will be synthesised qualitatively.
Ethics and dissemination: This review synthesises
published literature and presents no primary data.
Therefore, no ethical approval is required for this study.
Subsequent papers will provide greater detail on
results, within select categories, that represent gaps in
the literature base.
INTRODUCTION
E-cigarettes or electronic nicotine delivery
systems (ENDS) have recently attracted con-
siderable attention for several reasons.
Compared with combustible cigarettes, these
(1) deliver nicotine without combus-
tion, (2) are thought to be less toxic,1–8
(3) can be used to reduce nicotine craving/
withdrawal,3 9–13 (4) tend to be less expen-
sive2 3 8 14 15 and (5) can potentially help
one quit combustible cigarette smoking/
prevent relapse.1–4 6–8 15–21
While there is great variability in the
design and performance of ENDS within
and across brands, characterising features
include the use of a battery or other power
source, and a heating element that when
activated delivers an aerosol mist from a solu-
tion most often containing tobacco-derived
nicotine, ﬂavourings and other ingredi-
ents.22 23 ENDS typically fall into three cat-
egories: disposable ‘ciga-like’ products,
rechargeable ‘ciga-like’ products and larger
rechargeable products (ie, personal vapouri-
sers, tank systems). In addition to physical
and performance-related differences, these
categories of products differ in price, where
they are typically sold, and the type of ENDS
users that purchase them.14 24
Among some individuals, there is strong
debate and a polarisation of views about the
public health beneﬁts versus harms from use
of ENDS.25–27 Proponents argue this is a dis-
ruptive technology that has potential to
speed the demise of the combusted cigarette.
From this perspective, ENDS could present
an unprecedented opportunity to alleviate
the burden of tobacco-related death and
disease on a massive scale. Opponents are
concerned about minimising unintended
Strengths and limitations of this study
▪ This review systematically synthesises studies
related to electronic nicotine delivery systems
use across a broad range of study designs and
outcomes.
▪ The results of this study may inform future regu-
latory action and future research studies.
▪ This review will be limited to English language
and peer-reviewed articles.
▪ Owing to the volume of studies in the literature
base, the literature search was limited to one
database.
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consequences such as unforeseen health hazards related
to ENDS, dual use that might undermine cigarette
smoking cessation and the possibility that ENDS will
attract non-users, including youth and former cigarette
smokers.
The ENDS market is evolving, with new products
being rapidly introduced and marketed. Currently, there
is no independent entity charged with monitoring and
regulating ENDS products, but the US Food and Drug
Administration (FDA) Center for Tobacco Products
(CTP) has proposed a rule to deem ENDS as subject to
the Family Smoking Prevention and Tobacco Control
Act (Tobacco Control Act).28 Previous reviews have
addressed speciﬁc topics, including the health effects of
ENDS,29–48 the impact of ENDS on smoking cessa-
tion,38 49–53 product features,29 48 54 55 consumer percep-
tions,34 56 patterns of use34 57 and policies.58 There are
also several published comprehensive reviews about
the ENDS literature.59–63 However, rapid development in
manufacturing, marketing and consumer domains
related to ENDS will warrant frequent re-evaluation,
based on the state of the evolving science. The purpose
of this article is to describe a protocol for an ongoing
comprehensive review of the published scientiﬁc litera-
ture on ENDS.
METHODS AND ANALYSIS
Design
We will undertake a systematic review of empirical research
literature published in peer-reviewed journals on ENDS to
be updated at regular intervals and on an as-needed basis
to inform FDA public comment periods and other policy-
relevant information gathering sessions.
Eligibility criteria
Study design
Eligible studies are experimental studies, quasi-
experimental studies, observational studies (including
case–control, cohort and cross-sectional studies), case
reports, case series, qualitative studies and mixed
methods studies providing empirical data on ENDS.
Potential other sources will be obtained by emailing
experts and reviewing reference lists of included articles.
Outcome measures
We will accept a broad range of outcomes that will dem-
onstrate the impact of ENDS on individual-level and
population-level health. These are listed in table 1.
Published reviews, commentaries, letters to the editor,
editorials, practice guidelines, position statements and
study protocols will be excluded unless they present ori-
ginal data from the authors. This review will be limited
to English language studies published in peer-reviewed
journals (not limited to the USA). Preclinical/animal
studies will be excluded.
Search methods
We conducted an initial search in August 2013 using the
National Library of Medicine’s PubMed electronic data-
base and the following keywords: “e-cigarette*” OR
“electronic cigarette” OR “electronic cigarettes” OR
“electronic nicotine delivery”. We did not specify a start-
ing publication date because ENDS are a relatively new
class of tobacco products. Since the initial search, we
have conducted regular searches to identify new studies
on ENDS and added the medical subject heading
(MeSH) term “Electronic Cigarettes” that was intro-
duced in 2015 as well as “vape” OR “vaping” to our list
of search terms. Searches will be conducted at regular
intervals and on an as-needed basis to inform FDA
Table 1 Electronic nicotine delivery systems systematic
review study categories and outcomes
Study category Outcomes
Product features ▸ Product design
▸ Nicotine, propylene glycol,
flavouring, particulate matter and
other toxicant content
Health effects ▸ Effects of:
– Nicotine
– Tobacco-related toxicants
– Non-tobacco-specific toxicants
▸ Impact on:
– Cardiovascular system
– Lung function
– Blood count
– Other physiology
– Cognition
– Abuse liability/addictiveness
▸ Adverse events
▸ Cytotoxicity
Consumer
perceptions
▸ Awareness
▸ Product perceptions
▸ Interest
▸ Reasons for use
Patterns of use ▸ Ever, current and dual use with other
tobacco products
▸ Initiation/progression
▸ Smoking cessation/reduction
▸ Use among various groups: general
population, youth, young adults,
adults, current smokers, former
smokers, never-smokers, etc
Marketing ▸ Advertisement/promotion prevalence
and expenditure
▸ Claims and depictions
▸ Receptivity to advertising/promotion
▸ Marketing channels
Sales ▸ Market share/sales volume
▸ Retail and online availability
▸ Pricing
Policies ▸ Federal, state, local and
organisational
▸ Existing and proposed
▸ Public support for policy
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public comment periods and other policy-relevant infor-
mation gathering sessions. Reference lists of published
literature reviews on ENDS will be screened for add-
itional eligible studies.
Study selection
For the ﬁrst round of review to determine eligibility, one
reviewer will screen the article title and abstract for ref-
erence to ENDS. Articles that make it through this
round will then be reviewed in full text to determine
inclusion into one or more of the following categories:
(1) product features, (2) health effects, (3) consumer
perceptions, (4) patterns of use, (5) marketing, (6) sales
and (7) policies. At the point of data extraction,
reviewers will conﬁrm eligibility before entering the
study’s data in the review. If an article is excluded for
multiple reasons, only the primary reason for exclusion
will be noted. The hierarchy for identifying the reason
for exclusion when multiple reasons exist will be as
follows: (1) the article was not available in English,
(2) the article was not relevant to ENDS, (3) the study
included non-human participants or (4) the study did
not include original data. The remaining studies will be
retained for inclusion in the systematic review. If a study
meets the criteria for eligibility in the ﬁrst round, but
does not ﬁt into one of the seven categories listed above,
the team of reviewers will meet to discuss whether add-
itional categories should be added to capture emerging
themes in the scientiﬁc literature.
Quality assessment
Randomised studies assessing the impact of ENDS on
health effects, consumer perceptions or patterns of use
will be evaluated using the Cochrane Collaboration tool
for assessing risk of bias.64 For other study designs, we
will consider the study’s applicability or relevance to the
literature and note its limitations.
Data extraction
Data from included studies will be extracted into a stan-
dardised form developed in Microsoft Excel by a
number of reviewers (AMG, COC, OG, LT, LK, SWR, SF
and ACV), with each reviewer completing data extrac-
tion for a given category of studies. The form
will contain the following ﬁelds: (1) study objective(s);
(2) study details/methods (including study design, inter-
vention groups, number of experiments, equipment
used, setting, puff conditions and measurement condi-
tions); (3) target population; (4) sample size; (5) pro-
ducts tested, if applicable (including number, type,
brand name/model, nicotine content and ﬂavour of
products); (6) measures; (7) outcomes; (8) limitations;
(9) major conclusions and (10) funding source/author
disclosures. During this process, the form will be revised
if other relevant information is not captured in these
ﬁelds. In addition, individual reviewers will identify
other categories of the review (eg, product features and
health effects) in which the study should be included
based on the outcomes measured in that study. All com-
munications regarding the addition of studies to other
categories will be documented on a web-based project
management system available to all authors. This will
ensure that studies addressing multiple outcomes are
captured in all of the relevant sections of the review.
Data analysis
Following data extraction, we will create tables with
details and key outcomes for each study within each cat-
egory (ie, product features and health effects). In add-
ition, we will qualitatively synthesise studies by outcomes
measured and the main results. We intend to publish
subsequent papers on select outcomes to address gaps
in the literature base. Given the heterogeneity of the
included study designs and outcomes, we do not expect
to conduct meta-analyses of study results, assess meta-
biases or evaluate the body of evidence systematically
using a central framework (eg, GRADE). As the evi-
dence base grows, we will re-examine whether there are
a sufﬁcient number of similar studies on a single topic
to warrant conducting these evaluations.
ETHICS AND DISSEMINATION
This review synthesises published literature and presents
no primary data. Therefore, no ethical approval is
required for this study.
Publication plan
Findings from this systematic evidence review will be
disseminated in white papers, policy documents
(eg, federal docket submissions), fact sheets and peer-
reviewed journal articles.
STRENGTHS AND LIMITATIONS
This review is unique in three ways. First, whereas most
other reviews on ENDS have focused on a particular
outcome of interest,31 35 36 43 50 52 53 56 this review will
systematically synthesise studies related across a broad
range of study designs and outcomes on an ongoing
basis. Second, the review will be updated regularly and
in response to opportunities to inform policy and pro-
gramme decision-making. Third, the review will high-
light gaps in the literature to recommend areas for
future research in pace with the rapidly evolving tobacco
landscape and evidence base.
Limitations of the review include the restriction of eli-
gible studies to those that are peer-reviewed, indexed in
PubMed and available in English language. Owing to
the volume of studies in the literature base, the search is
limited to one database, and a single author conducts
the title and abstract review for a given search. While an
individual author conducts data extraction for a given
category of studies, we have developed a process for
identifying studies that should be categorised under
multiple outcomes and a team approach to communica-
tion to reduce bias in data extraction.
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